Lisocabtagene maraleucel vs standard of care as second-line therapy for LBCL: 3-year follow-up from the phase III TRANSFORM trial

After a median follow-up of 33.9 months, median event-free survival (EFS) was longer in the liso-cel arm vs SOC arm (29.5 months vs 2.4 months), and the 36-month EFS rate was higher in patients treated with liso-cel vs SOC (45.8% vs 19.1%). 

The best overall response rate was higher following treatment with liso-cel vs SOC (87% vs 49%), with complete response rates of 74% vs 43%. 

Median progression-free survival (PFS) was not reached in the liso-cel arm and was 6.2 months in the SOC arm, and the 36-month PFS rate was higher with liso-cel vs SOC (50.9% vs 26.5%). 

Median overall survival (OS) was not reached in either arm, and the 36-month OS rate was higher with liso-cel vs SOC (62.8% vs 51.8%). 

Median duration of response (DoR) was not reached in the liso-cel arm and was 9.1 months in the SOC arm, and the 24-month DoR rate was higher following liso-cel treatment vs SOC (60.5% vs 43.5%).  

Grade 1–3 cytokine release syndrome and neurological events were low in the liso-cel arm, with no Grade 4–5 events, and patients needed minimal use of tocilizumab and steroids to manage these, with no prophylactic use.